Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers

Cancer Letters

Volumn 162, Issue SUPPL. 1, 2001, Pages

  Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epstein Barr virus; L( )nucleoside; Viral associated cancers

Indexed keywords

CLEVUDINE; EMTRICITABINE; LAMIVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER PREVENTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; VIRUS CARCINOGENESIS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DIOXOLANES; HEPATITIS B VIRUS; HERPESVIRUS 4, HUMAN; HUMANS; NEOPLASMS; NUCLEOSIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL; VIRUS DISEASES; ZALCITABINE;

ANIMALIA; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 4;

EID: 0035139830     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00650-9     Document Type: Article

References (20)

1. Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma
2. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
3. Deoxycytidine deaminase-resistant stereoisomer is the active form of (()-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
4. Characterization of a dCTP transport activity reconstituted from human mitochondria
5. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine
6. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
7. Molecular Biology Commentary. Mitochondrial Toxicity of Antiviral Nucleoside Analogs
8. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
9. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro
10. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5-fluorocy tidine
11. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5-fluorocy tidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro
12. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
13. Interaction of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodeficiency virus drug design
14. Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′- didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model
15. Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides
16. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil
17. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil
18. Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-beta-L-arabinofuranosyl)-5-methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases
19. Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein-Barr virus agents